Skip to content
Search

Latest Stories

Well Pharmacy names new non-executive director

Well Pharmacy has announced the appointment of Noel Gordon as its new non-executive director.

Gordon, who has extensive experience of driving technological innovation and business transformation in the retail and the healthcare sectors, starts his new role at the pharmacy chain from next month.


The appointment is crucial for Well which has over 750 community pharmacies nationwide and is the third largest digital pharmacy in the sector.

Gordon is currently a non-executive director of NHS England, chair of Healthcare UK’s Advisory Board and former chair of NHS Digital.

Previously an economist and a banker, he spent most of his career in consultancy with stints at Accenture and Booz Allen & Hamilton based in both London and New York.

Commenting on his appointment, he said: “I am delighted to be joining the Well Board at such an important time in the pharmacy sector. As consumer behaviours, expectations and needs change, and the market landscape continues to evolve, Well is ideally placed to embrace new technologies to deliver real benefits to patients and local communities across the UK.”

In welcoming the appointment, Bestway group CEO Lord Zameer Choudrey, said: “We are delighted to have someone of Noel’s calibre on-board. His wealth of experience in using digital technologies to transform industries and drive strategic implementation will be a valued addition to the Well Board.”

Seb Hobbs, Well CEO, added: “Noel brings a wealth of experience in digital and technology to the Well Board. His skills and experience will be invaluable as we continue to innovate and build the best pharmacy experience in the UK.”

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
It is official: Opella is now a standalone company

Opella launches as an independent company to redefine the future of self-care.

Photo credit: gettyimages

Opella becomes standalone company as Sanofi-CD&R deal closes

Opella has officially become a standalone company, following the completion of Sanofi’s sale of a controlling 50.0% stake to private equity firm Clayton, Dubilier & Rice (CD&R).

Sanofi retains a significant shareholding with a 48.2% stake while Bpifrance holds the remaining 1.8% stake.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less